Roche has announced that it has obtained the CE Mark for its Accu-Chek SugarView app. This paves the way for the launch of the innovative diabetes management solution in Europe and further countries around the world requiring the CE Mark.
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter. It is designed to help non-insulin-dependent people with Type 2 diabetes or pre-diabetes live healthier lives in-between doctors’ visits.
Now officially classified as in-vitro diagnostics (IVD) software, the app will be made widely accessible by Roche first for certain smartphone models via the Google Play Store, thus enabling broader access to therapy relevant information for non-insulin dependent people with Type 2 diabetes or pre-diabetes.
The Accu-Chek SugarView app determines the blood glucose range using the Accu-Chek Active test strip and two photos taken off the strip with a smartphone camera. An easy-to-follow, step-by-step guide leads the user through the testing process. A dedicated algorithm assigns the blood glucose result on the test strip to one of the categories ranging from ‘low’ to ‘very high’. Based on the testing result, it combines the blood glucose range with basic information on how to take action, such as to do some exercise or to eat something.
Marcel Gmuender, Global Head of Roche Diabetes Care has commented, “The broad launch of this state-of-the art digital solution can offer a huge benefit to people in-between doctors’ visits and to those not having access to appropriate diabetes care and blood glucose monitoring. Non-insulin dependent people with Type 2 diabetes or pre-diabetes can gain a better understanding of how to live a healthier life through learning how their blood glucose range can vary as a result of their actions. Accu-Chek SugarView is an easy-to-use app. In addition, it bypasses the need for a blood glucose meter, making it a very affordable and convenient diabetes management solution. This is especially crucial in emerging markets with often limited access to care and scarce healthcare resources, as the app enables availability of relevant therapy information and support in everyday life.”
